• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伯氏疏螺旋体——另一种新兴的蜱传病原体。

Borrelia miyamotoi - another emerging tick-borne pathogen.

出版信息

Epidemiol Mikrobiol Imunol. 2021 Summer;70(2):118-130.

PMID:34412488
Abstract

Borrelia miyamotoi is an emerging tick-borne pathogen phylogenetically belonging to spirochaetes causing relapsing fever. It is primarily transmitted by ticks from the Ixodes ricinus complex, similarly to borreliae causing Lyme borreliosis. Small rodents can serve as reservoir hosts. It is widespread in mild climate areas of the northern hemisphere, with constant low prevalence in ticks, in the range of units of percent. To date more than 200 human cases have been described including five cases of meningoencephalitis in immunocompromised patients. Clinical features of illness are non-specific, characterized by fever, fatigue, chills, headaches, muscles and joint pains. It can be treated with antibiotics. The diagnostic approach includes mainly PCR and serological methods. This review summarizes current knowledge on B. miyamotoi with an emphasis on taxonomy, ecology of vectors and reservoir hosts, geographical distribution, diagnosis and treatment of the disease. The review also highlights the need for an accurate determination of the etiology of the disease and its differentiation from Lyme borreliosis and human granulocytic anaplasmosis.

摘要

伯氏疏螺旋体是一种新兴的蜱传病原体,在系统发生上属于螺旋体,可引起回归热。它主要通过硬蜱属(Ixodes ricinus 复合体)传播,与引起莱姆病的伯氏疏螺旋体相似。小型啮齿动物可以作为储存宿主。它广泛分布于北半球气候温和地区,蜱中的流行率一直很低,单位为百分比。迄今为止,已经描述了超过 200 例人类病例,包括 5 例免疫功能低下患者的脑膜炎病例。疾病的临床特征是非特异性的,表现为发热、疲劳、寒战、头痛、肌肉和关节疼痛。它可以用抗生素治疗。诊断方法主要包括 PCR 和血清学方法。本文综述了伯氏疏螺旋体的最新知识,重点介绍了其分类学、媒介和储存宿主的生态学、地理分布、疾病的诊断和治疗。本文还强调了准确确定病因及其与莱姆病和人类粒细胞埃立克体病的区别的必要性。

相似文献

1
Borrelia miyamotoi - another emerging tick-borne pathogen.伯氏疏螺旋体——另一种新兴的蜱传病原体。
Epidemiol Mikrobiol Imunol. 2021 Summer;70(2):118-130.
2
First detection of Borrelia miyamotoi in Ixodes ricinus ticks from northern Italy.首次在意大利北部的蓖子硬蜱中检测到 Miyamotoi 螺旋体。
Parasit Vectors. 2018 Mar 20;11(1):130. doi: 10.1186/s13071-018-2713-z.
3
Assessment of Borrelia miyamotoi in febrile patients and ticks in Alsace, an endemic area for Lyme borreliosis in France.评估发热患者和法国莱姆病流行地区阿尔萨斯的蜱中的伯氏疏螺旋体。
Parasit Vectors. 2020 Apr 17;13(1):199. doi: 10.1186/s13071-020-04071-9.
4
[Borrelia miyamotoi: a recently identified human pathogenic tick-borne relapsing fever spirochete].[宫本疏螺旋体:一种最近被确认的由蜱传播的人类致病性回归热螺旋体]
Orv Hetil. 2017 Jul;158(29):1124-1130. doi: 10.1556/650.2017.30791.
5
Borrelia miyamotoi infection in nature and in humans.日本疏螺旋体在自然界及人类中的感染情况。
Clin Microbiol Infect. 2015 Jul;21(7):631-9. doi: 10.1016/j.cmi.2015.02.006. Epub 2015 Feb 18.
6
Borrelia miyamotoi: a widespread tick-borne relapsing fever spirochete.伯氏疏螺旋体:一种广泛传播的蜱传回归热螺旋体。
Trends Parasitol. 2015 Jun;31(6):260-9. doi: 10.1016/j.pt.2015.03.008. Epub 2015 Apr 16.
7
Borrelia miyamotoi: A human tick-borne relapsing fever spirochete in Europe and its potential impact on public health.宫本疏螺旋体:欧洲一种通过蜱传播的人类复发性发热螺旋体及其对公共卫生的潜在影响。
Adv Med Sci. 2016 Sep;61(2):255-260. doi: 10.1016/j.advms.2016.03.001. Epub 2016 Mar 21.
8
Borrelia miyamotoi in vectors and hosts in The Netherlands.荷兰媒介和宿主中的伯氏疏螺旋体新种。
Ticks Tick Borne Dis. 2017 Mar;8(3):370-374. doi: 10.1016/j.ttbdis.2016.12.012. Epub 2016 Dec 30.
9
Borrelia miyamotoi and Co-Infection with Borrelia afzelii in Ixodes ricinus Ticks and Rodents from Slovakia.斯洛伐克蓖麻硬蜱和啮齿动物中存在的宫本疏螺旋体以及与阿氏疏螺旋体的共感染情况
Microb Ecol. 2017 May;73(4):1000-1008. doi: 10.1007/s00248-016-0918-2. Epub 2016 Dec 19.
10
Detection of Borrelia miyamotoi in Ixodes ricinus ticks in Southern Moravia - risk for public health.在摩拉维亚南部的硬蜱中检测到 Miyamotoi 螺旋体-对公共卫生的风险。
Epidemiol Mikrobiol Imunol. 2022 Spring;71(1):57-59.